The November 2025 article published in The Journal of Hepatology and titled “Non-invasive tests for MetALD and alcohol-related liver disease” is summarized in what follows, and makes these key points–

— Non-invasive tests are available and validated as first-line assessments in the clinical care of patients at risk of MetALD and ALD.

–Non-invasive tests should be applied to shift the paradigm from late diagnosis to early detection.

— Management of patients with MetALD and ALD should follow a holistic approach due to their increased risk of cardiovascular diseases and cancer.

— With emerging drug trials in patients with alcohol-related liver fibrosis and cirrhosis, there is an unmet need for non-invasive tests to monitor treatment response and assess alcohol consumption.

First, what is MedALD?

Now, the summary of the journal article–

Big picture

• MetALD (metabolic + alcohol) and ALD drive a disproportionate share of cirrhosis and deaths despite being less prevalent than MASLD.
• The field diagnoses too late. Non-invasive tests (NITs) can flip the paradigm to early detection, risk stratification, and longitudinal monitoring, and will be central to upcoming drug trials.

Prevalence & risk

• MASLD ~31–34% of adults; MetALD ~2–8%; ALD ~1–4%.
• Liver-event/mortality risk: MetALD/ALD ≈45% vs MASLD ≈4% over time → these groups need proactive detection.

Screening & cost-effectiveness

• Primary care is the front door; most future decompensators had prior health-system contact.
• Sequential NIT pathways are cost-effective and can reduce drinking simply by screening/feedback.
  • Example strategies shown as cost-effective:
    • ELF → TE referral pathway in excess drinkers (low incremental cost per QALY).
    • TE screening in at-risk primary care (favorable ICER).
• Awareness, stigma reduction, and policy support are essential system enablers.

Which NITs work (diagnosis & staging)

• First-line, wide-net tests (cheap, scalable):
  • FIB-4 (and NFS) – good to rule out advanced fibrosis in low-prevalence settings; AUROC ~0.85 for advanced fibrosis in MetALD cohorts.
  • LiverRisk and LiverPRO (composite blood scores) — population/primary-care friendly; LiverPRO is CE-marked.
• Direct fibrosis tests (higher performance):
  • ELF – AUROC ~0.90–0.92 for advanced fibrosis in ALD; robust prognostic value.
  • PRO-C3 / ADAPT – AUROC ~0.85–0.88; promising but with less real-world breadth than ELF.
• Imaging:
  • Transient elastography (TE, liver stiffness measurement) – AUROC ~0.90 for ≥F3 and cirrhosis in ALD.
  • Important: LSM drops with alcohol withdrawal/inflammation resolution; repeat after reduced drinking if inflammatory markers are high. Standard quality criteria matter (≥10 valid shots; IQR ≤30%).

Steatosis

• Steatosis tools (CAP, ultrasound metrics) have modest accuracy; alcohol-related “pure steatosis” still raises 5-year cirrhosis and mortality risk—don’t ignore it.

Prognosis & monitoring

• TE outperforms biopsy stage for predicting events in early ALD. Indicative risk bands:
  • <10 kPa → minimal 4-yr decomp risk
  • 10–15 kPa → ~21% liver event risk
  • >15 kPa → ~54% liver event risk
• Dynamic monitoring matters: LSM ↑ ≥20% over ~2 years → ~4× higher decomp risk; LSM change outperforms FIB-4/MELD change.
• Abstinence is pivotal at all stages; recompensation on sustained abstinence slashes liver-related deaths (>90% reduction reported).

Measuring alcohol use (don’t rely on self-report)

• PEth (blood) = best objective marker for recent (2–4 wk) intake.
  • Practical thresholds: <20 ng/mL ≈ abstinent/low; ≥80 ng/mL flags ≥~4 drinks/day in CLD; ≥200 ng/mL suggests heavy chronic use.
  • Strong predictor of decompensation/mortality vs self-report; under-reporting is common.
• EtG: urine (past ~3 days); hair (up to ~1 month) — useful adjuncts.
• AUDIT / AUDIT-C remain useful screeners but should be paired with biomarkers.

Care model

• Patients with ALD/MetALD face high extrahepatic risks (CV disease, cancer, infections, mental health).
• Management must be multidisciplinary: hepatology + primary care + addiction + mental health + cardiometabolic care, with nutrition, exercise, smoking cessation, and strong social support.
• AUD treatment (CBT + anti-craving meds) improves survival.

Trials & what’s coming

• Expect more ALD/MetALD pharmacotherapy trials.
• GLP-1 RAs (e.g., semaglutide) showed histologic inflammation reversal and meaningful fibrosis benefit in phase III MASLD/MASH; real-world signals suggest reduced alcohol-related hospitalizations.
• FGF21 analogs may offer dual antifibrotic and alcohol-reducing effects.
• Omics biomarkers (proteomics/lipidomics) show high diagnostic/prognostic potential (e.g., proteomic panels AUROC ~0.92; low sphingolipids predict poor survival) but need standardization and validation.